# Will Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays?

Source: https://onco.cc/trials/nct02022358/  
OnCo record `nct02022358` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Glucarpidase, Methotrexate and Leucovorin in Osteosarcoma, run by University College, London, recorded as terminated on the registry.

## Summary

Will Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays? is a phase 2 interventional study registered as NCT02022358 by University College, London, with 34 participants recorded, started 2007-07 and due to reach its primary completion in 2015-06. Interventions recorded: Glucarpidase, Methotrexate, Folinic Acid. Conditions recorded: Osteosarcoma, Spindle Cell Sarcoma of Bone.

Linked to the drug Glucarpidase because the registry names it among its interventions and Osteosarcoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02022358
- Phase: 2
- Setting: A Randomised, Cross-over Phase II Study to Investigate the Efficacy and Safety of Glucarpidase for Routine Use After High Dose Methotrexate in Patients With Bone Sarcoma
- Sponsor: University College, London
- Enrolled: 34

## Sources

- ClinicalTrials.gov NCT02022358: https://clinicaltrials.gov/study/NCT02022358

## Connected records

- cancers: [Osteosarcoma](https://onco.cc/cancers/osteosarcoma/)
- drugs: [Glucarpidase](https://onco.cc/drugs/glucarpidase/), [Leucovorin (folinic acid)](https://onco.cc/drugs/leucovorin/), [Methotrexate](https://onco.cc/drugs/methotrexate/)

---
JSON: https://onco.cc/api/v1/entities/nct02022358.json